Susquehanna International Group
ORKA

Susquehanna International Group’s Oruka Therapeutics ORKA Stock Holding History

Susquehanna International Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$971K Buy
19,800
+5,100
+35% +$177K ﹤0.01% 7963
2025
Q4 		$446K Sell
14,700
-57,900
-80% -$1.61M ﹤0.01% 9071
2025
Q3 		$1.4M Buy
+72,600
New +$1.08M ﹤0.01% 6562
2023
Q2 		– Sell
-5,792
Closed -$138K – 13330
2023
Q1 		$138K Buy
5,792
+1,967
+51% +$51.8K ﹤0.01% 10993
2022
Q4 		$108K Sell
3,825
-67,533
-95% -$1.73M ﹤0.01% 10891
2022
Q3 		$1.76M Sell
71,358
-2,217
-3% -$62.6K ﹤0.01% 5186
2022
Q2 		$2.2M Buy
73,575
+69,933
+1,920% +$1.98M ﹤0.01% 4706
2022
Q1 		$101K Sell
3,642
-83
-2% -$2.06K ﹤0.01% 11911
2021
Q4 		$96K Sell
3,725
-2,367
-39% -$71.3K ﹤0.01% 12177
2021
Q3 		$216K Buy
6,092
+1,267
+26% +$46.8K ﹤0.01% 11326
2021
Q2 		$202K Buy
4,825
+2,950
+157% +$123K ﹤0.01% 11582
2021
Q1 		$82K Buy
1,875
+833
+80% +$43.7K ﹤0.01% 11927
2020
Q4 		$50K Buy
+1,042
New +$51.9K ﹤0.01% 10754

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Susquehanna International Group's ORKA Position: Q1 2026 in Review

Susquehanna International Group increased its Oruka Therapeutics (ORKA) stake by 142% in Q1 2026, buying an estimated $428K and bringing the position to 20,984 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #7816.

Susquehanna International Group first reported a position in ORKA in Q2 2015 and has held it in 15 quarters since. The position peaked at $3.59M in Q1 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Susquehanna International Group held 20,984 shares of Oruka Therapeutics worth $1.03M as of Q1 2026.
  • Susquehanna International Group bought 12,319 Oruka Therapeutics shares in Q1 2026, an estimated $428K.
  • Oruka Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7816 holding.
  • Susquehanna International Group first reported a position in Oruka Therapeutics in Q2 2015 and has held it in 15 quarters since.
  • Susquehanna International Group's Oruka Therapeutics position peaked at $3.59M in Q1 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.